Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

Background: The risk of falls and bone fractures with sodium-glucose co-transporter-2 (SGLT2) inhibitors has been characterized by conflicting evidence. Therefore, we decided to investigate the reporting probability of falls and fractures by comparing SGLT2 inhibitors with DPP4 inhibitors. Methods A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascolo, Annamaria, Rafaniello, Concetta, di Mauro, Gabriella, Ruggiero, Donatella, Campitiello, Maria Rosaria, Donniacuo, Maria, Berrino, Pasquale Maria, Rossi, Francesco, Paolisso, Giuseppe, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657831/
https://www.ncbi.nlm.nih.gov/pubmed/38027019
http://dx.doi.org/10.3389/fphar.2023.1245642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657831/
https://www.ncbi.nlm.nih.gov/pubmed/38027019
http://dx.doi.org/10.3389/fphar.2023.1245642

Ejemplares similares